Company: OPGN
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001829126-25-009312
Chunk: 3

Company: OPGEN INC
Filing Date: 2025-11-19
Form: 10-Q
Item: Part I, Item 1
Chunk 3
---
) increase in cash, cash equivalents and restricted cash

    (896,442
    )

    481,343

    Cash and cash equivalents and restricted cash at beginning of period

    1,612,915

    1,454,085

    Cash and cash equivalents and restricted cash at end of period
     
    $
    716,473

    $
    1,935,428

    Supplemental disclosure of cash flow information

    Cash paid for interest
     
    $
    8,777

    $
    4,317

    Supplemental disclosures of noncash investing and financing activities

    Settlement of deferred compensation and severance
     
    $
    -

    $
    1,333,285

    Issuance of common stock upon conversion of preferred stock
     
    $
    -

    $
    2,950,217

See accompanying notes to unaudited condensed consolidated financial statements.

4

OpGen, Inc. and Subsidiaries

Notes to Unaudited Condensed Consolidated Financial Statements

September 30, 2025

Note 1 – Organization

OpGen, Inc. (“OpGen” or the “Company”) was incorporated in Delaware in 2001. In April 2020, OpGen completed a business combination transaction with Curetis N.V., a public company with limited liability under the laws of the Netherlands, pursuant to which the Company acquired all the shares of Curetis GmbH, a private limited liability company organized under the laws of the Federal Republic of Germany (“Curetis”), and certain other assets and liabilities of Curetis N.V., including Ares Genetics GmbH (“Ares Genetics”), a wholly-owned subsidiary of Curetis.

From inception until November 2023, OpGen operated as a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. The Company, along with its subsidiaries, Curetis and Ares Genetics, developed and commercialized molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. In November 2023, Curetis and Ares Genetics filed petitions for insolvency in their local jurisdictions. The insolvency filings resulted in the elimination of the Company’s authority and power to act on behalf of the subsidiaries and accordingly, this loss of control resulted in the Company decons